HCPCS Level II J2350: Ocrelizumab Injection, 1 mg
Commercial payers pay $391 on average nationally for this procedure.
HCPCS Level II code J2350 describes the billed drug unit for ocrelizumab, 1 mg, intended for intravenous administration as a disease‑modifying therapy for demyelinating disorders; the service type is injectable biologic drug and the typical site of service is an infusion center or outpatient hospital/clinic where IV biologic therapies are delivered.
For related coverage guidance, see recent payer policy updates: Epithelial Cell Cytology in Breast Cancer Risk Assessment, Chemotherapy Observation or Inpatient Hospitalization (for New Mexico Only), Umbilical Cord Blood Harvesting and Storage for Future Use (for Indiana Only).
Customize your policy alerts
Sign up for hcpcs J2350 policy alerts
Get alerted when payer policies referencing J2350 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial reimbursement for HCPCS J2350 centers around the BUCA average commercial rate of $391.40, which provides a useful midpoint against individual payer distributions. Blue Cross Blue Shield’s interquartile spread (P75–P25) is $6.90, Cigna’s spread is $0.30, UnitedHealth Group’s spread is $5.40, Aetna’s spread is $44.30, and BUCA’s spread is $12.20. These spreads indicate Cigna and Blue Cross Blue Shield exhibit the tightest concentration around their midpoints, while Aetna shows a markedly wider dispersion driven by outlier high values that push its P75–P25 range well above peers.
Comparing central tendency and dispersion, UnitedHealth Group and Blue Cross Blue Shield cluster near the low- to mid-$60s for medians and P50 values, while Cigna sits essentially at $59.40 as its median. Aetna’s very large maximum and broader spread contrast with the steadier patterns at Cigna and Blue Cross Blue Shield; BUCA’s average at $391.40 sits above most payer means but with a moderate interquartile range, reflecting higher overall commercial pricing with less extreme variability than Aetna.